State Of Wisconsin Investment Board Ngm Biopharmaceuticals Inc Transaction History

State Of Wisconsin Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.6 - $1.31 $29,220 - $63,797	-48,700 Reduced 41.38%	69,000 $59,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $50,366 - $161,652	-47,968 Reduced 28.95%	117,700 $125,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $51,593 - $95,786	21,145 Added 14.63%	165,668 $429,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $32,345 - $46,953	-8,695 Reduced 5.67%	144,523 $589,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $416,821 - $1.58 Million	122,235 Added 394.52%	153,218 $769,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $17,336 - $24,331	-1,377 Reduced 4.26%	30,983 $405,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $12,061 - $19,950	-1,140 Reduced 3.4%	32,360 $415,000
Q4 2020 Feb 03, 2021	SELL	$16.21 - $31.44 $68,082 - $132,048	-4,200 Reduced 11.14%	33,500 $1.02 Million
Q1 2020 May 06, 2020	BUY	$10.0 - $19.51 $276,000 - $538,476	27,600 Added 273.27%	37,700 $465,000
Q3 2019 Nov 12, 2019	BUY	$13.09 - $18.19 $132,209 - $183,719	10,100 New	10,100 $140,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.